May 13, 2015

M·CAM International

M·CAM is a research provider focused on intellectual property and intangible assets.

Celgene Revlimid® Validity Review

Celgene's $CELG patent families protecting their Revlimid® product do not appear to meet the criteria for legitimate patent protection.

Loading PDF

More from M·CAM International

M·CAM International

M·CAM and CNBC release the CNBC IQ100 Index

M·CAM and CNBC have partnered to create the CNBC IQ100, a data-driven index of the 100 companies best using technology to invest in and profit from new business opportunities. M·CAM's proprietary algorithms are used to select companies ...

Oct 28, 2016

Dex Wheeler, M·CAM International

Patents in Focus: IBM, GRPN, ZTS, IPGP

Groupon vs IBM On Monday, Groupon sued IBM claiming infringement of patent U.S. 7,856,360. Groupon claims IBM’s WebSphere platform infringes the ‘360 patent, which was originally granted to Hoozware, Inc. Upon review, the Groupon patent appears ...

May 13, 2016

Dex Wheeler, M·CAM International

Despite Business Practices, Valeant’s IP Value Remains Key to Future

While questionable business practices have caused volatility in its share price and outlook, VRX’s intellectual property (IP) value remains unchanged. As asset sales look more and more likely, understanding the IP protecting VRX’s products is ...

Apr 27, 2016

Dex Wheeler, M·CAM International

Announcing the Release of New Debt and Equity Analyst Reports

Based on proprietary intellectual property (IP) and financial analysis systems and models, M·CAM’s reports provide a unique, IP-driven perspective on enterprise value and security of corporate revenues. Attached are report examples covering Kodak ...

Apr 26, 2016

M·CAM International

Chimerix, Inc. Report

Chimerix $CMRX has a strong intellectual property position, making it an attractive target for acquisition by a larger firm.

Jun 09, 2015

M·CAM International

Avago Technologies Suing Maxim Integrated Products

Avago's $AVGO infringement suit against Maxim Integrated $MXIM stands on weak legs. When large chip-makers battle over intellectual property, it can have material impacts on revenue streams. In this case, Maxim appears to be in a good position to ...

Jun 04, 2015

M·CAM International

Actavis: Allergan's Battle at the PTAB

How will Actavis $ACT owned Allergan hold up with IPR challenges to its Restasis and Combigen patents before the PTAB?

May 08, 2015

Global Climate Investing Survey 2025

Sponsored by Robeco

Our fifth annual survey shows that enthusiasm for climate investment continues to vary by region. Europe has reclaimed its leadership from Asia-Pacific, which topped last year’s survey, while interest in the US has dropped to new lows.

The most important insight of the day

Get the Harvest Daily Digest newsletter.

Support
Privacy Policy
GDPR
CCPA
Terms
Copyright

© 2025 Harvest Exchange Corp

What is Harvest?

Harvest is a digital marketing platform that connects investors with financial firms, products and services through behavioral data.

Become a publisher

Distribute your firm's investment insights on the world's largest investor community. Learn more